Literature DB >> 22078895

[Stability of Le Fort I impaction osteotomies].

C Vincent1, J M Mercier, J-P Perrin, R H Khonsari.   

Abstract

INTRODUCTION: Long-term results of Le Fort I osteotomy with vertical impaction for maxillary vertical excess may be not stable. We had for aim to analyze postoperative maxillary and dental displacement after a Le Fort I vertical impaction osteotomy, to identify causes of relapse. PATIENTS AND METHODS: A clinical and radiological evaluation was made on postoperative occlusion (early and late). The position of three bone (O: lower orbit; P: greatest palatine convexity; T: lowest part of the mandibular foramen) and of three dental landmarks (I: occlusal edge of the upper incisor; i: occlusal edge of the lower incisor; m: first molar distal vestibular cuspid) was measured in a standardized method on pre-surgical, early and late (1 to 2.5 years) postoperative cephalometric X rays. Eighteen patients were operated by the same surgeon for maxillary anterior vertical excess and underwent Le Fort I impaction osteotomy, alone or associated with a mandibular osteotomy. Stability was defined by a postoperatory displacement smaller than 1mm.
RESULTS: All patients had stable bone landmarks. Three patients had unstable dental landmarks due to relapse. DISCUSSION: Impaction maxillary osteotomy provides stable bone results for maxillary facial height excess. Unsatisfactory outcome is always due to postoperative dental and alveolar displacement. These results correlate to published data.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22078895     DOI: 10.1016/j.stomax.2011.10.009

Source DB:  PubMed          Journal:  Rev Stomatol Chir Maxillofac        ISSN: 0035-1768


  1 in total

1.  Prosthognathic rehabilitation of a patient with underlying skeletal discrepancy- a case report.

Authors:  Ashish R Jain; James Antony Bhagat M; Deepak Nallaswamy; Vinod Narayanan; Padma Ariga
Journal:  J Clin Diagn Res       Date:  2014-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.